Showing results (221-230 of 302) with videos related to
Sort By:
Pageof 31
Clinical Lymphoma, Myeloma & Leukemia|August 24, 2013
Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemiaPaolo Strati, Naval Daver, Farhad Ravandi, et al.Therapeutic Advances in Medical Oncology|February 18, 2026
Gastrointestinal adverse events following brentuximab vedotin and polatuzumab vedotin therapyAndrew G Kuang, Malek Shatila, Jay S Shah, et al.Nature Medicine|August 29, 2022
Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphomaNathalie Scholler, Regis Perbost, Frederick L Locke, et al.Blood|May 16, 2012
Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year resultsIssa F Khouri, Rima M Saliba, William D Erwin, et al.Haematologica|March 19, 2026
Salvage high-dose chemotherapy and autologous stem cell transplant consolidation following relapse after CAR-T cell for large B-cell lymphomaJeremy Ramdial, Erica Agbadiba, Misha Hawkins, et al.American Journal of Hematology|December 23, 2014
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndromePaolo Strati, Hagop Kantarjian, Farhad Ravandi, et al.British Journal of Haematology|April 8, 2017
CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemiaPaolo Strati, Sameer A Parikh, Kari G Chaffee, et al.Blood Advances|May 1, 2019
Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphomaChelsea C Pinnix, Sarah A Milgrom, Chan Yoon Cheah, et al.The Lancet. Oncology|December 3, 2014
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trialNathan H Fowler, R Eric Davis, Seema Rawal, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2025
Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin LymphomaSattva S Neelapu, Julio C Chavez, Alison R Sehgal, et al.Pageof 31